Ann: $8M PRIVATE PLACEMENT & LAUNCH OF SPP, page-12

LBT Innovations continues its dominance on medical AI, signing a major deal with leading EU distributor, launches CR and gets the green light from The John Hopkins Hospital Former Cochlear Executive Brent Barnes is leading LBT Innovations (ASX: LBT) to new heights in recent months as the company sets its sights on global expansion. On announcing their recent deal with Beckman Coulter, Brent commented "This represents a significant step forward in our commercialisation strategy for the technology, adding the scale and strength of the Beckman Coulter brand to support our sales efforts in the region". Highlights include: Recently signs marketing agreement with Beckman Coulter, a leading globaldistributor, marketing LBT Innovations' APAS®Independence across Europe. Receives green light from The John Hopkins Hospital evaluation of its APAS® system on patient samples for methicillin-resistant staphylococcus aureus, or MRSA. APAS® is already the only U.S. Food and Drug Administration-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates. Announces capital raise with early indications of strong market interest. Beckman Coulter LBT Innovations has signed a marketing agent agreement with Beckman Coulter for the marketing of theAPAS® Independence in Europe. Under the three-year agreement, Beckman Coulter will act as the marketing agent forAPAS®Independence and will receive a fixed referral fee from CCS for each sale including incentives for the completion of early sales. CCS (Clever Culture Systems) is LBT Innovations' 50:50 joint venture company in the commercialisation ofAPAS®and it will take charge of the sales, installation, and maintenance of the product.Read more.. APAS® and the FDA The APAS® Independence technology is designed to streamline microbiology work by automatically screening and interpreting culture plates in a lab. While the product has already been approved in the States for its urine analysis module, LBT needs to create a new module for each different type of bacteria specimen analysed, hence today's application. LBT is now looking to get itsAPAS®Independence with a Methicillin-resistant Staphylococcus aureus (MRSA) analysis module approved by the FDA. Read more.. LBT Innovations CEO and MD Brent Barnes discusses recent news - Source: The Market Herald

The John Hopkins Hospital gives green light LBT Innovations says testing of itsAPAS®Independence tech by Johns Hopkins has passed with flying colours. The testing was conducted at The Johns Hopkins Hospital and School of Medicine, in Maryland, United States. The three-month study tested the efficacy of theAPAS®tech across 4,603 samples manually checked by microbiologists. The results were remarkable, withAPAS®recording no false negatives, and identifying three true positives that were missed by the microbiologists.Read more.. APAS®Independence- Innovating AI and intelligent imaging for the future of healthcare APAS®(Automated Plate Assessment System) Independence is a platform technology that automates culture-plate screening and interpretation. Thousands of agar plates are assessed every day and each one has to be thoroughly examined by a microbiologist. APAS®Independence speeds-up this process by automatically screening, interpreting, and sorting the plates. This frees up the microbiologist's time. A soft launch is expected in late 2020, which will then be followed by European meetings in 2021, with organisations like the European Congress of Clinical Microbiology and Infectious Diseases. TheAPAS® Independence currently has regulatory clearance for use in the United States (FDA), Europe (CE Mark) and Australia (TGA) where there are >2,000 laboratories that meet the target customer profile and technology. TheAPAS®Independence technology has been showcased to the world’s leading microbiologists and diagnostic companies at leading microbiology conferences worldwide Ramps up for capital raising Tuesday 7th July 2020: LBT Innovations announces a capital raise after requesting its shares be placed in a trading halt on the ASX. While the exact details of the capital raise are yet to be announced, the company stated the money would go towards expanding sales activities of itsAPAS®Independence technology in Europe. Shares in LBT were last trading for 19 cents per share on July 6, 2020, before being placed in the trading halt. Discover more on LBT Innovations